EGFR TKI (3rd generation) · small molecule
nazartinib
1 active trials, targeting EGFR. Not approved for any biomarker on marked.bio yet.
Also known as EGF816.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| EGFR exon 19 deletion / L858R | 1 | 7 | Phase 1 |
Sponsors
Industry sponsors leading active biomarker-selected trials of nazartinib.
- Novartis 1
Trials
1 of 7 trials shown
-
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
nazartinibtrametinibribociclibnaporafenibcapmatinibgefitinib FDA EU
…tologically confirmed locally advanced (stage IIIB) or metastatic (stage IV) EGFR mutant (ex19del, L858R) NSCLC.
EGFR exon 19 deletion / L858REGFR-mutant Non-small Cell Lung Cancer
-
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
nazartiniberlotinib FDA EUgefitinib FDA EU
…ic, stage IIIB/ IIIC or stage IV NSCLC with documented EGFR activating mutation (L858R or ex19del)
EGFR exon 19 deletion / L858RCarcinoma, Non-small Cell Lung
-
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
nazartinibgefitinib FDA EU
An EGFR sensitizing mutation must be detected in tumor tissue.
EGFR exon 19 deletion / L858RLung Cancer
-
Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.
…nts in Phase Ib and Phase II Groups 1 to 4: locally documented EGFR mutation L858R and/or ex19del, or a characterized de novo EGFR T790M mutation (or other rare activating mutations that …
EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
-
Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
…ticenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients …
EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
-
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
…amenable to definitive multi-modality therapy including surgery) or metastatic (stage IV) EGFR mutant NSCLC.
EGFR exon 19 deletion / L858RAdvanced Non-small Cell Lung Cancer
-
EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
Patients must have NSCLC harbouring EGFR p.L858R or EGFR del19 as assessed by local testing.
EGFR exon 19 deletion / L858RBronchial Neoplasms
No trials match these filters.